Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data ENANTA PHARMACEUTICALS INC files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
88.3
103
207
205
122
97.1
86.2
79.2
67.6
65.3
Research and development
40.5
57.5
94.9
142
137
174
165
164
131
107
General and administrative
17
20.7
23.4
26.2
27.4
32.5
45.5
52.9
57.9
43.9
Operating income
30.8
24.6
88.3
36.7
-41.6
-110
-124
-137
-122
-85.3
Interest expense
0.05
0.04
0
0
5.15
10.9
7.68
Interest income
1.74
2.53
Other non-operating income
1.72
2.33
4.79
8.82
6.62
1.99
1.66
6.21
3.9
1.8
Pre-tax income
32.6
26.9
93.1
45.6
-35
-108
-122
-131
-118
-83.5
Income tax
10.9
9.24
21.2
-0.83
1.15
-28.6
-0.43
2.82
-1.74
-1.66
Net income
21.7
17.7
72
46.4
-36.2
-79
-122
-134
-116
-81.9
EBITDA
32.5
26.8
90.8
40
-38
-106
-121
-135
-119
-80.8
EPS, basic
1.14
0.93
3.74
2.37
-1.81
-3.92
-5.91
-6.38
-5.48
-3.84
EPS, diluted
1.13
0.91
3.48
2.21
-1.81
-3.92
-5.91
-6.38
-5.48
-3.84
Shares, basic (weighted)
18.9
19.1
19.3
19.6
0.02
0.02
0.02
0.02
0.02
0.02
Shares, diluted (weighted)
19.2
19.4
20.7
21
0.02
0.02
0.02
0.02
0.02
0.02
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
16.6
65.7
63.9
51.2
87.1
57.2
44
85.4
37.2
32.3
Short-term investments
158
245
284
300
187
205
285
211
157
Receivables
12.8
10.6
67.2
51.3
23.5
23.6
20.3
8.61
6.65
6.88
Other current assets
9.23
3.54
4.45
15.3
13.7
14.2
13.4
13.3
12.4
8.59
Total current assets
232
238
380
402
437
319
312
423
300
204
Property, plant and equipment
8
8.05
8.37
10.9
8.6
5.94
6.17
11.9
32.7
35.4
Lease right-of-use assets
7.02
4.71
23.6
22.8
40.7
37.5
Long-term investments
70
16.4
65
32.6
108
29.3
0
0
Other non-current assets
0.09
0.09
0.09
0.09
0.7
0.8
0.09
0.09
Total assets
281
327
414
490
486
439
375
462
377
281
Accounts payable
3.38
3.71
4.75
6.69
5.74
9.54
6
4.1
8
1.95
Accrued liabilities
4.51
7.97
9.89
15.9
14.2
22.4
20.9
18.3
13.5
12.8
Total current liabilities
7.89
21
16
22.6
24.2
36.2
29.8
62.8
57.5
48.6
Lease liabilities
3.84
1.13
22.4
21.2
53.9
54.8
Other non-current liabilities
2.04
2.41
2.9
3.1
1.08
0.56
0.45
0.66
0.23
0.26
Total liabilities
11.3
25
20.5
27.3
30.6
39.4
54.1
246
248
216
Paid-in capital
242
256
277
298
327
351
398
425
451
470
Retained earnings
27.6
45.4
117
164
128
48.6
-73.2
-207
-323
-405
Other comprehensive income
0.02
-0.11
-0.4
0.15
0.84
-0.38
-3.72
-1.17
0.3
-0.34
Shareholders' equity
270
302
394
462
456
399
321
217
129
64.7
Total equity
270
302
394
462
456
399
321
217
129
64.7
Total liabilities and equity
281
327
414
490
486
439
375
462
377
281
Shares outstanding
19
19.1
19.4
19.7
20.1
20.2
20.8
21.1
21.4
21.4
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
21.7
17.7
72
46.4
-36.2
-79
-122
-134
-116
-81.9
Depreciation and amortization
1.66
2.14
2.52
3.26
3.64
3.33
2.97
2.37
2.34
4.59
Stock-based compensation
9.35
13.1
15.8
19.2
19.6
21
27
28.2
26.8
18.6
Deferred income tax
-2.29
-1.65
1.86
-3.14
-18.3
0.35
0
0
Change in receivables
2.45
2.23
-56.6
15.9
27.8
-0.08
3.26
11.7
1.97
-0.24
Change in payables
1.45
0.63
1.32
1.79
-0.88
3.77
-4.63
-1.15
-0.41
-1.31
Cash from operations
35.8
52.7
29.2
71.4
7.09
-70
-84.8
-103
-78.8
-19.3
Capital expenditures
-4.74
-2.51
-2.98
-5.42
-1.45
-0.75
-2.13
-9.06
-17.9
-12.9
Purchases of investments
-192
-251
-293
-549
-339
-307
-171
-373
-307
-210
Sales and maturities of investments
154
239
Cash from investing
-43.7
-4.57
-35.4
-86.7
19.8
37
54.9
-53.6
58.2
40.3
Stock issued
1.03
1.08
6.24
6.85
10.5
3.61
21.3
2.21
0.15
0.15
Cash from financing
2.71
1.02
4.41
2.57
8.98
3.08
20
198
-27.6
-26.6
Net change in cash
-5.15
49.1
-1.77
-12.7
35.9
-29.9
-9.85
41.4
-48.2
-5.54
Free cash flow
31.1
50.1
26.2
66
5.64
-70.7
-86.9
-112
-96.7
-32.2
Interest paid
0
1.99
11.7
8.79
Income taxes paid
12.6
1.59
26.1
12.7
0.11
0.03
0
4.9
0.24
0.11
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $11.88 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-90.0%
Operating income / revenue.
EBITDA margin
-82.5%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-96.7%
Pre-tax income / revenue.
Net margin
-96.9%
Net income / revenue.
FCF margin
-56.6%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-54.1%
Cash from operations / revenue.
Return on equity (ROE)
-62.6%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-21.3%
Net income / average total assets.
Return on invested capital (ROIC)
-68.6%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
132.1%
Research and development expense / revenue.
Stock-based pay / revenue
23.4%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
2.5%
Capital expenditures / revenue.
D&A / revenue
7.5%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-3.4%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-8.8%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-11.8%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-49.8%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-41.4%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-32.3%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-25.5%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-9.2%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-10.4%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
0.8%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
1.2%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
1.4%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
3.76x
Current assets / current liabilities.
Quick ratio
3.62x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
3.50x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$2.24
Revenue / diluted weighted shares.
FCF per share
-$1.27
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.21
Cash from operations / diluted weighted shares.
Book value per share
$3.47
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
5.30x
Market cap / revenue.
P/B
3.42x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
3.42x
Market cap / tangible book value, when positive.
EV/Sales
2.40x
Enterprise value / revenue.
FCF yield
-10.7%
Free cash flow / market cap.
Earnings yield
-18.3%
Net income / market cap (the inverse of P/E).
What was ENANTA PHARMACEUTICALS INC's revenue in fiscal 2025?
ENANTA PHARMACEUTICALS INC reported revenue of $65.3M for fiscal 2025, 3.4% lower than the year before.
Was ENANTA PHARMACEUTICALS INC profitable in fiscal 2025?
No. It reported a net loss of $81.9M.
How much free cash flow did ENANTA PHARMACEUTICALS INC generate in fiscal 2025?
Cash from operations of $19.3M minus capital expenditures of $12.9M left free cash flow of -$32.2M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.